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MDA-MB-231 bone metastases but not primary breast cancer lead to progressive weight loss and muscle weakness.
(a) left: X-ray analysis revealed large osteolytic lesions (arrows) in mice receiving MDA-MB-231 cells via the intra-cardiac route at 4-weeks post-inoculation. right: MDA-MB-231 tumor cells visible in the bone (arrows) by H&E staining.
(b) left: Body weight loss in mice with MDA-MB-231 bone metastases (percent change in total body weight over baseline) (n=12). right: Dual energy X-ray absorptiometry (DXA) scan revealed loss of both lean and fat content in mice with bone metastases at 4-weeks post-inoculation (n=12).
(c) left: Mid-calf cross-sectional area, measured by in vivo microCT imaging, was lower in mice with bone metastases at 4-weeks post-inoculation (n=5). right: Lower weight of individual muscles dissected from the lower hindlimb (n=10) of mice with MDA-MB-231 bone metastases; extensor digitorum longus (EDL), tibialis anterior (TA), soleus (SOL), gastrocnemius (Gastroc) compared to non-tumor control mice.
(d) EDL muscle fiber diameter was lower in mice with bone metastases (n=200 fibers from n=5 histological sections) compared to non-tumor control mice.
(e) RyR1 was oxidized (DNP) and nitrosylated (CysNO) and RyR1-calstabin1 co-immunoprecipitation from EDL muscle was lower at 3-and 4-weeks post-inoculation (n=3) compared to non-tumor control mice.
(f) Lower ex vivo specific force of the EDL muscle at 3-and 4-weeks post-inoculation (n=9) compared to non-tumor control mice.
(g) Osteolytic lesions and quantitation of lesion area measured by X-ray imaging of all 4 limbs of mice with breast cancer bone metastases at 2, 3 and 4-weeks post-inoculation (n=8).
(h) Bone destruction correlated to muscle weakness in mice with bone metastases (relationship between specific force (120Hz) and lesion area measured by X-ray imaging) at 4-weeks postinoculation (n=8).
(i) left: Mice with MDA-MB-231 primary tumors in the mammary fat pad (without bone metastases) did not have reduced body weight over baseline compared to non-tumor bearing mice (n=12). right: Mice with primary tumor did not have altered body composition (DXA scan to measure both lean and fat content in mice) (n=9) compared to non-tumor control mice.
(j) left: Mice with primary tumor did not have altered individual muscles dissected from the lower hindlimb (n=8). right: Mid-calf cross-sectional area was measured by in vivo microCT imaging and showed no difference in mice with MDA-MB-231 primary tumors (n=10) compared to non-tumor control mice.
Data are mean ± s.e.m., (b,f,I) Two-way ANOVA; (b,c,e,g,i) One-way ANOVA with multiple comparisons; (c,d,j,j) t-test; (h) Pearson's correlation. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Bone metastases models with osteolytic or mixed osteolytic/osteoblastic bone lesions are associated with muscle weakness.
(a) left: A549 bone metastases are osteolytic. middle: In vivo forelimb grip strength. right: Ex vivo specific force of the EDL muscle are lower in mice with A549 lung cancer bone metastases at 6-weeks post-inoculation (n=10) compared to non-tumor control mice.
(b) left: Weight of individual muscles dissected from the lower hindlimb at 6-weeks post-inoculation (n=10) was lower for EDL, TA and Gastroc muscles compared to non-tumor control mice. middle left: Mice with bone metastases lose weight compared to non-tumor mice (n=10). middle right: DXA scan revealed loss of both lean and fat content (n=10) compared to non-tumor control mice. right: Mid-calf cross-sectional area, measured by in vivo microCT imaging, was lower in mice with bone metastases (n=4) compared to non-tumor control mice.
(c) RyR1 was oxidized (DNP) and nitrosylated (CysNO) and calstabin1 binding to RyR1 was lower by co-immunoprecipitation from skeletal muscle in mice with A549 bone metastases (EDL; n=3) compared to non-tumor control mice. (f) RyR1 from muscle of mice with RWGT2 bone metastases was oxidized and nitrosylated and depleted of calstabin1 compared to non-tumor controls (n=10).
(g) left: MCF-7 breast cancer in bone is osteoblastic/osteolytic. right: Mice with MCF-7 breast cancer in bone caused lower EDL ex vivo specific force (n=10) compared to non-tumor control mice.
(h) EDL muscle weight was not lower in mice with MCF-7 cancer in bone compared to non-tumor control mice. right: Mice with MCF-7 cancer in bone caused lost weight compared to non-tumor control animals.
(i) RyR1 was oxidized and nitrosylated and calstabin1 binding was lower in mice with MCF-7 cancer in bone (n=4) compared to non-tumor control mice.
Data are mean ± s.e.m., (a,d,e,g) Two-way ANOVA with Bonferroni multiple comparisons; (b,c,e,f,h,i) t-test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
Non-Tumor JJN3
Non-Tumor JJN3 Prostate cancer bone metastases and multiple myeloma cause bone destruction and muscle weakness.
(a) left: PC-3 prostate cancer bone metastases are osteolytic. middle: Reduced forelimb grip strength (n=8) in mice with PC-3 bone metastases compared to non-tumor control mice. right: Ex vivo EDL specific force (n=8) in mice with PC-3 bone metastases compared to non-tumor control mice.
(b) Mice with PC-3 bone metastases had left: lower individual muscle weight (n=8), middle: reduced body weight (percent change over baseline) (n=8), right: reduced lean and fat content (n=8) compared to non-tumor control mice.
(c) RyR1 from skeletal muscle of mice with PC-3 bone metastases was oxidized and nitrosylated and had lower calstabin1 binding to the RyR1 complex compared to non-tumor controls (n=4).
(d) left: Radiographs showing bone destruction in mice with JJN-3 tumors. middle: Ex vivo specific force of the contralateral extensor digitorum longus (EDL) muscle was lower in mice bearing JJN-3 tumor (n=6) compared to non-tumor control mice. right: RyR1 was oxidized (DNP) and nitrosylated (CysNO) and calstabin1 binding to RyR1 was lower by co-immunoprecipitation from EDL skeletal muscle (n=3) compared to non-tumor control mice.
(e) left: Weight of individual muscles dissected from the lower hindlimb at 6-weeks post-inoculation (n=6) were not changed in mice with JJN-3 cells compared to non-tumor control mice. middle: JJN-3 tumors were not associated with body weight loss (6-weeks post-inoculation) (n=6) compared to nontumor control mice. right: Relationship between specific force (120Hz) and lesion area (measured in all limbs) by X-ray imaging (n=7).
(f) left: ZR75-1 breast cancer bone metastases are osteoblastic. middle: Mice with ZR75-1 breast cancer bone metastases did not have reduced forelimb grip strength (n=10) compared to non-tumor control mice. right: Mice with ZR75-1 breast cancer bone metastases have lower ex vivo EDL specific force compared to non-tumor animals (n=10).
(g) left: Mice with ZR75-1 bone metastases had similar muscle weight (n=10) compared to non-tumor control mice. middle left: Body weight (n=10), and (middle right); body composition (n=10) compared to non-tumor controls. right: Mice with ZR75-1 bone metastases did have increased mid-calf crosssectional area compared to non-tumor controls (n=4).
(h) Mice with ZR75-1 bone metastases had lower ex vivo EDL specific force but RyR1 was not oxidized or nitrosylated and calstabin1 binding was intact (n=10) compared to non-tumor control mice.
Data are mean ± s.e.m. Rycal S107 does not affect body weight or tumor burden and muscle weakness is not due to loss of body weight due to food consumption.
(a) left: Osteolytic lesion area (assessed by radiographs) in mice with breast cancer bone metastases treated either with vehicle or S107 were similar (n=19). middle: Number of osteoclasts (OCL) per mm at the tumor-bone interface (measured by histomorphometry) (n=15) in mice treated either with vehicle or S017. right: Tumor burden in mice with breast cancer bone metastases was similar in mice treated with S107 compared with vehicle (n=10).
(b) left: Percent change in body weight (n=10) was reduced in mice with breast cancer bone metastases compared to non-tumor control mice, and was not changed by treatment with either S107 or vehicle. right: DXA scan revealed loss of both lean and fat content in mice with bone metastases and this change is not affected by treatment (n=10).
(c) left: Weight of individual muscles dissected from the lower hindlimb (n=10) was lower in mice with breast cancer bone metastases compared to non-tumor controls and was not affected by treatment. middle: EDL muscle fiber cross-sectional area (n=200 fibers from n=3 histological sections) was lower in mice with breast cancer bone metastases compared to non-tumor controls and was not affected by treatment.. right: Mid-calf cross-sectional area (measured by in vivo microCT imaging (n=5)) was lower in vehicle treated mice with bone metastases compared to non-tumor control mice, but not in mice treated with S107.
(d) Mice with breast cancer and bone metastases had reduced food consumption (by up to 40%) in the last week before death. To determine whether muscle weakness in mice with bone metastases was due to reduced food consumption, we restricted food available to normal healthy mice by 30-40% for one week. Despite a significant decrease in body weight due to a loss of both muscle and fat mass, mice subjected to this caloric restriction showed no decrease in forelimb grip strength, and no lowering in EDL muscle specific force compared to pair-fed mice. Mice with bone metastases exhibit reduced food consumption during approximately the last week of life (n=8 cages).
(e) left: 30-40% caloric restriction of healthy 8-week-old female nude mice (age matched to last week of bone metastatic models) leads to loss of body weight (calorie restriction initiated at day 18) (n=10) compared to pair-fed mice. middle left: Lean and fat content of mice after 1 week of calorie restriction measured by DXA scan (n=10) compared to pair-fed mice. middle right: Weight of individual muscles dissected from the lower hindlimb after 1 week of calorie restriction (n=10) compared to pair-fed mice. right: In vivo mid-calf cross-sectional area of mice after 1 week of calorie restriction (n=5) was lower compared to pair-fed mice.
(f) left: Forelimb grip strength was not affected by calorie restriction (n=10) compared to pair-fed mice. right: Ex vivo muscle contractility of the extensor digitorum longus (EDL) muscle was not affected by calorie restriction (n=10) compared to pair-fed mice.
Data are mean ± s.e.m., (a,c,e) t-test; (b,d,e,f) Two-way ANOVA; (b,c) One-way ANOVA with multiple comparisons. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. SMAD3 phosphorylation is higher in mice with osteolytic or mixed osteolytic/osteoblastic bone metastases and muscle weakness; blocking TGFβ-RI kinase activity (SD-208) or inhibiting bone resorption (ZA) prevented weight loss and lowered tumor burden in muscle from mice with bone metastases.
(a) top row: SMAD3 phosphorylation relative to total SMAD3 was not changed in muscle samples from mice with MDA-MB-231 primary tumors (without bone metastases) compared to non-tumor control mice. SMAD3 phosphorylation was increased in mice with with A549 osteolytic lung cancer bone metastases compared to non-tumor control mice, and RWGT2 mixed osteolytic/osteoblastic lung cancer bone metastases (n=4 each) compared to non-tumor control mice. middle row: SMAD3 phosphorylation was increased in MCF-7 mixed osteolytic/osteoblastic breast cancer bone metastases compared to non-tumor control mice, PC-3 osteolytic prostate cancer bone metastases compared to non-tumor control mice, and JJN-3 osteolytic multiple myeloma compared to non-tumor control mice (n=4 each). bottom row: In contrast, SMAD3 phosphorylation relative to total SMAD3 expression in mice with ZR75-1 breast cancer bone metastases was not changed compared to nontumor control mice. Total skeletal muscle proteins from MDA-MD-23 mice with bone metastases were analyzed by mass spectroscopy in order to identify oxidized proteins.
